Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

LRMR
Larimar Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:57 PM EDT
2.24USD+3.226%(+0.07)2,533,551
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 8, 2025 9:28:30 AM EDT
2.25USD+3.687%(+0.08)4,715
After-hours
May 8, 2025 4:39:30 PM EDT
2.35USD+4.911%(+0.11)9,409
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
05:01AM EST  41 Biggest Movers From Yesterday   Benzinga
Nov 22, 2021
07:00AM EST  Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021.   GlobeNewswire Inc
Nov 15, 2021
07:00AM EST  Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 16, 2021.   GlobeNewswire Inc
Nov 12, 2021
07:28AM EST  Larimar Therapeutics Q3 EPS $(0.92) Down From $(0.64) YoY   Benzinga
07:00AM EST  Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today reported its third quarter and year to date September 30, 2021 operating and financial results.   GlobeNewswire Inc
Sep 17, 2021
03:10PM EDT  Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet   Benzinga
Sep 16, 2021
08:00AM EDT  Larimar Therapeutics to Participate in SVB Leerink CybeRx Series:   GlobeNewswire Inc
Sep 2, 2021
04:01PM EDT  Larimar Therapeutics to Present at the Morgan Stanley 19th Annual   GlobeNewswire Inc
Aug 19, 2021
07:00AM EDT  Larimar Therapeutics Announces Upcoming Oral Presentation at the   GlobeNewswire Inc
Aug 12, 2021
07:00AM EDT  - Reported positive proof-of-concept and dose response data from Phase 1 program evaluating CTI-1601 in patients with Friedreichs ataxia (FA)   GlobeNewswire Inc
Jul 8, 2021
04:01PM EDT  Larimar Therapeutics to Present at the William Blair Biotech Focus   GlobeNewswire Inc
Jul 5, 2021
07:25AM EDT  Notable Insider Buys In The Past Week: Asana, Transocean, IPOS, SPACS And More   Benzinga
Jun 11, 2021
07:00AM EDT  Larimar Therapeutics to Present at the JMP Securities Life   GlobeNewswire Inc
Jun 2, 2021
10:57PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (Larimar or the Company) (NASDAQ:LRMR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
02:34PM EDT  Mid-Afternoon Market Update: Build-A-Bear Rises After Q1 Results; Travere Therapeutics Shares Drop   Benzinga
12:25PM EDT  Mid-Day Market Update: Nasdaq Surges 70 Points; Larimar Therapeutics Shares Plummet   Benzinga
10:37AM EDT  Shares of Larimar Therapeutics, Inc. (LRMR) tanked over 40% on Wednesday morning. The company's stock was impacted by the news that its CTI-1601 clinical program has been placed on hold by the FDA and that a previously announced private placement financing will be terminated.   RTTNews
10:18AM EDT  Mid-Morning Market Update: Markets Mixed; Dick's Sporting Goods Beats Q1 Estimates   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
05:56AM EDT  Larimar Stock Craters After FDA Clinical Hold on Friedreich's Ataxia Program   Benzinga
May 25, 2021
11:40PM EDT  Larimar Therapeutics Inc. (LRMR) said Tuesday that the United States Food and Drug Administration has placed a clinical hold on the CTI-1601 clinical program.   RTTNews
05:51PM EDT  Larimar Therapeutics Shares Set To Resume Trade At 6:10 p.m. EDT   Benzinga
05:45PM EDT  Larimar Therapeutics Shares Halted After News Disseminated; Shares Down 3.3%   Benzinga
05:42PM EDT  Larimar Therapeutics Reports FDA Clinical Hold On CTI-1601, Termination Of Recently Announced Private Placement Financing   Benzinga
05:42PM EDT  Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and   GlobeNewswire Inc
May 21, 2021
03:47PM EDT  Larimar Shares Trade Higher On $95M Capital Raise, CTI-1601's Priority Medicines Tag In Europe   Benzinga
09:19AM EDT  Larimar Therapeutics Reports $95M Private Placement Financing   Benzinga
09:18AM EDT  Larimar Therapeutics Announces $95 Million Private Placement Financing   GlobeNewswire Inc
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
04:32PM EDT  Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation For CTI-1601 In Friedreich's Ataxia   Benzinga
04:31PM EDT  Larimar Therapeutics Receives European Medicines Agency Priority   GlobeNewswire Inc
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
03:35PM EDT  Why Is Larimar Therapeutics Stock Plunging Despite Positive CTI-1601 Data?   Benzinga
02:38PM EDT  Mid-Afternoon Market Update: Dow Tumbles Over 500 Points; Rekor Systems Shares Plummet   Benzinga
12:11PM EDT  Mid-Day Market Update: 3D Systems Rises After Upbeat Earnings; Larimar Therapeutics Shares Slide   Benzinga
10:23AM EDT  Shares of Larimar Therapeutics, Inc. (LRMR) are slipping nearly 14% on Tuesday morning. The clinical-stage biotechnology company focused on rare diseases reported positive data from early stage study of CTI-1601 as a treatment for Friedreich's Ataxia.   RTTNews
09:36AM EDT  Larimar Therapeutics Reports Positive CTI-1601 Data From Friedreich's Ataxia Trial   Benzinga
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
07:01AM EDT  Larimar Therapeutics Reports Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases In Frataxin Levels in Patients With Friedreich's Ataxia   Benzinga
07:00AM EDT  Larimar Therapeutics Reports Positive Topline Phase 1 Clinical   GlobeNewswire Inc
May 10, 2021
04:43PM EDT  Larimar Therapeutics Q1 EPS $(0.76) Up From $(1.10) YoY   Benzinga
04:05PM EDT  - Topline data from placebo-controlled Phase 1 program in Friedreich's ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET   GlobeNewswire Inc
Mar 4, 2021
07:11AM EST  Larimar Therapeutics Q4 EPS $(0.89) Up From $(1.00) YoY   Benzinga
07:00AM EST  -- Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich'sataxia (FA) patients -- Placebo-controlled Phase 1 trials in FA patients remain on track for topline data in Q2 2021 -- Cash and investments of $92.6 million as of December 31, 2020   GlobeNewswire Inc
Feb 18, 2021
04:01PM EST  Larimar Therapeutics to Present at the SVB Leerink 10th Annual   GlobeNewswire Inc
Feb 1, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021   Benzinga
07:58AM EST  William Blair Initiates Coverage On Larimar Therapeutics with Outperform Rating   Benzinga
Dec 15, 2020
08:00AM EST  Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open onMonday, December 21, 2020.   GlobeNewswire Inc
Dec 8, 2020
07:36AM EST  Larimar Therapeutics Announces Completion Of Dosing Of The Single Ascending Dose Clinical Trial In Friedreich's Ataxia Patients And Provides Program Update   Benzinga
07:30AM EST  - Preliminary datasuggest that single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg   GlobeNewswire Inc
Nov 13, 2020
08:00AM EST  Larimar Therapeutics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
08:19AM EST  Larimar Therapeutics Q3 EPS $(0.64) Up From $(1.42) YoY   Benzinga
08:00AM EST  Phase 1 trials evaluating CTI-1601 as a treatment for Friedreichs ataxiaon track for topline data in 1H2021   GlobeNewswire Inc
Oct 20, 2020
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 13, 2020
08:00AM EDT  Larimar Therapeutics Announces Formation of Scientific Advisory Board   GlobeNewswire Inc
Sep 21, 2020
09:58AM EDT  Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.   GlobeNewswire Inc
Sep 10, 2020
08:00AM EDT  Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020, at 11:45 a.m. EDT.   GlobeNewswire Inc
Aug 11, 2020
07:22AM EDT  Larimar Therapeutics Q2 EPS $(1.21)   Benzinga
07:00AM EDT  Larimar Therapeutics Reports Second Quarter 2020 Operating and   GlobeNewswire Inc
Aug 4, 2020
08:00AM EDT  Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020, at 8:35 a.m. EDT.   GlobeNewswire Inc
Jul 28, 2020
08:14AM EDT  Larimar Therapeutics Announces Positive Opinion On Orphan Drug Designation Received From EMA For CTI-1601   RTTNews
08:05AM EDT  Larimar Therapeutics Announces Positive Opinion On Orphan Drug Designation Received From European Medicines Agency For CTI-1601 For The Treatment Of Friedreich's Ataxia   Benzinga
08:01AM EDT  Larimar Therapeutics Announces Positive Opinion on Orphan Drug   GlobeNewswire Inc
Jul 20, 2020
04:15PM EDT  Larimar Therapeutics Announces Dosing Of Patients In Third Cohort Of Phase 1 SAD Trial Of CTI-1601 For Treatment Of Friedreich's Ataxia   Benzinga
04:15PM EDT  Larimar Therapeutics Announces Dosing of Patients in Third Cohort   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC